Overall rank by patents
#11,377
of 50,000 tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Onward Medical N.v.
USPTO PatentsView assignee record - 27 granted patents across 9 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).
27
Total patents granted
9
CPC technology areas
11.8
Avg claims per patent
-
5-year grant velocity
The verdict
According to USPTO PatentsView, Onward ranks #11,377 of 50,000 tracked US assignees by granted-patent volume, with 27 patents across 9 technology areas.
- #11,377
- of 50,000 US assignees by volume
- Top 15%
- by Innovation Score (49.2/100)
- 11.8
- avg claims per patent
Portfolio overview
Onward Medical N.v. has been granted 27 US utility patents between 2022 and 2025, placing Onward Medical N.v. at #11,377 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.8 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Onward Medical N.v. is one of the more focused assignees in the PatentsView dataset. By volume, Onward sits between Osiris Therapeutics, Inc. (27 patents, rank #11,373) and Patlite Corporation (27 patents, rank #11,381) - the closest US assignees by grant volume. The composite Innovation Score of 49.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Historical data spans 2022 through 2025, with 27 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Onward Medical N.v.'s 11.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 9 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Who files at Onward's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Osiris Therapeuti…
OSIRIS THERAPEUTICS, INC.
27 patents
- Okta
Okta, Inc.
27 patents
- Oldcastle Buildin…
Oldcastle Building Products Canada Inc.
27 patents
- Onepin
OnePIN, Inc.
27 patents
- Optiscan Biomedic…
OptiScan Biomedical Corporation
27 patents
- Optumsoft
OptumSoft, Inc.
27 patents
- Pason Systems
PASON SYSTEMS CORP.
27 patents
- Patlite
PATLITE CORPORATION
27 patents
- Onward Medical ◀
Onward Medical N.V.
27 patents
What this shows Onward holds 27 patents at rank #11,377, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Onward
By rank, the assignees closest to #11,377 in granted patent volume.
- Osiris Therapeutics, Inc. #11,373 · 27 patents
- Okta, Inc. #11,374 · 27 patents
- Oldcastle Building Products Canada Inc. #11,375 · 27 patents
- Onepin, Inc. #11,376 · 27 patents
- Optiscan Biomedical Corporation #11,378 · 27 patents
- Optumsoft, Inc. #11,379 · 27 patents
- Pason Systems Corp. #11,380 · 27 patents
- Patlite Corporation #11,381 · 27 patents
Leaders in A61N (Electrotherapy)
Other assignees with the most granted patents in Onward's primary technology class.
- Medtronic, Inc. 2,200 in class
- Boston Scientific Neuromodulation Corporation 1,080 in class
- Cardiac Pacemakers, Inc. 1,037 in class
- Pacesetter, Inc. 609 in class
- ZOLL Medical Corporation 556 in class
- Koniniklijke Philips N.v. 534 in class
- Cochlear Limited 449 in class
- Varian Medical Systems, Inc. 296 in class
Onward's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 9 | 33.3% |
| 2023 | 9 | 33.3% |
| 2024 | 5 | 18.5% |
| 2025partial year | 4 | 14.8% |
Which technologies does Onward Medical N.v. patent most?
Top 9 of 9 technology areas
Grant record at a glance
Portfolio Volume 27 grants
CPC subclasses 9
Avg. claims / grant 11.8
Historical grant data only; it does not rate legal strength or current strategy.
Frequently Asked Questions
Where does Onward Medical N.v. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Onward Medical N.v. ranks #11,377 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Onward Medical N.v. hold?
Onward Medical N.v. holds 27 US utility patents granted between 2022 and 2025, spanning 9 technology areas.
What is Onward Medical N.v.'s Innovation Score?
Onward Medical N.v. has an Innovation Score of 49.2 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Onward Medical N.v. focus on?
Onward Medical N.v.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 20 patents. Grants appear in 9 CPC subclasses total.
Is Onward Medical N.v.'s patent grant rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Onward Medical N.v..
What does claim depth mean for Onward Medical N.v.'s patents?
Onward Medical N.v.'s patents average 11.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Onward Medical N.v. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Onward's 27 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Onward ranks #11,377 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.